Vimarsana
Biggest News Aggregation in the World

Page 19 - Mc Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mc Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mc Services Today - Breaking & Trending Today

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance - Vimarsana News

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance

Issuer: Mainz BioMed N.V. / Key word: Study results Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results...

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA - Vimarsana News

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA

Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ,...

EQS-News: Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis - Vimarsana News

EQS-News: Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis

EQS-News: Imcyse SA / Key word(s): Study Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis  13.09.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Imcyse Announces Complet...

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81% - Vimarsana News

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 -- Mainz Biomed N.V. , a...

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities. - Vimarsana News

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.

Affluent Medical Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities. 13-Sep-2023 / 17:45...